Search

Your search keyword '"ixekizumab"' showing total 132 results
Start Over Descriptor "ixekizumab" Publication Type News
132 results on '"ixekizumab"'

1. Eli Lilly and Company UK

Subjects
Olaratumab, Ixekizumab, Pemetrexed, Pharmaceutical industry, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

2. Eli Lilly and Company UK

Subjects
Olaratumab, Ixekizumab, Pemetrexed, Pharmaceutical industry, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

3. Eli Lilly and Company UK

Subjects
Olaratumab, Ixekizumab, Pemetrexed, Pharmaceutical industry, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

4. Eli Lilly and Company UK

Subjects
Olaratumab, Ixekizumab, Pemetrexed, Pharmaceutical industry, Adalimumab, Medical economics, Partnerships, Production management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

5. Eli Lilly and Company UK

Subjects
Olaratumab, Ixekizumab, Pemetrexed, Pharmaceutical industry, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

6. Eli Lilly and Company UK

Subjects
Olaratumab, Ixekizumab, Pemetrexed, Pharmaceutical industry, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

7. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

8. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

9. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

10. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

11. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

12. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

13. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

14. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

15. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

16. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

17. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

18. Australia makes severe back-neck pain & cardiovascular treatment affordable

Subjects
Neck pain -- Drug therapy, Ixekizumab, Rivaroxaban, Business, international, Law
Abstract

Thousands of Australians with debilitating back and joint pain will have access to a life changing treatment option through the Pharmaceutical Benefits Scheme (PBS). From December 1, access to Taltz [...]

Published
2020

19. Lilly reports positive data from multiple psoriasis trials

Subjects
Eli Lilly and Co., Ixekizumab, Psoriasis -- Care and treatment, Pharmaceutical industry, Arthritis -- Care and treatment, Adalimumab, Business, international, Law, Taltz (Medication)
Abstract

Eli Lilly and Company has reported that multiple long-term and post-hoc analyses of the monoclonal antibody Taltz (ixekizumab) showed sustained efficacy in patients with psoriasis and psoriatic arthritis. This includes [...]

Published
2020

20. Delivery Of Medicinal Products With The Active Substance Ixekizumab

Subjects
Ixekizumab, Business, international
Abstract

Contract notice: Delivery of medicinal products with the active substance ixekizumab The subject of the public contract is the provision of continuous supplies of medicinal products with the active substance [...]

Published
2020

21. Psoriasis Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery

Subjects
Drugs, Ixekizumab, Psoriasis -- Drug therapy, Pharmaceutical industry, Fluocinolone, COVID-19 -- Drug therapy, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Reportlinker.com announces the release of the report 'Psoriasis Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery' - https://www.reportlinker.com/p05967821/?utm_source=GNW 2 billion in 2019 to $14.4 billion in [...]

Published
2020

22. Psoriasis Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery

Subjects
Drugs, Ixekizumab, Psoriasis -- Drug therapy, Pharmaceutical industry, Fluocinolone, COVID-19 -- Drug therapy, Business, international, Law
Abstract

(GlobeNewswire) - Reportlinker.com announces the release of the report 'Psoriasis Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery' - https://www.reportlinker.com/p05967821/?utm_source=GNW 2 billion in 2019 to $14.4 billion in [...]

Published
2020

23. Psoriasis Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery

Subjects
Pfizer Inc., Eli Lilly and Co., Drugs, Ixekizumab, Psoriasis -- Drug therapy, Pharmaceutical industry, Fluocinolone, COVID-19 -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

New York, Sep 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- Reportlinker.com announces the release of the report 'Psoriasis Drugs Global Market Report 2020-30: Covid 19 Impact and Recovery' - https://www.reportlinker.com/p05967821/?utm_source=GNW [...]

Published
2020

24. Pemetrexed And Ixekizumab Drug Supply

Subjects
Ixekizumab, Pemetrexed, Business, international
Abstract

Contract Awarded for Pemetrexed and ixekizumab drug supply Tender base budget Amount: Presupuesto base de licitacin sin impuestos 471,620.00 Euros Amount (excluding taxes): 990,402.00 Euros Amount of Award Total amount [...]

Published
2020

25. EU Contract Notice: Krajska zdravotni Issues contract notice|solicitation for 'Czechia-Usti nad Labem: Immunosuppressive agents'

Subjects
Ixekizumab, Immunosuppressive agents, Contract agreement, General interest, News, opinion and commentary
Abstract

Luxembourg: Krajska zdravotni has issued contract notice/solicitation for 'Czechia-Usti nad Labem: Immunosuppressive agents' Reference no: 2020/S 170-411008 Posted on: 02/09/2020 Notice Type: Supplies Deadline for All responses: 02/10/2020 Description: The [...]

Published
2020

26. Delivery Of Medicinal Products With The Active Substance Ixekizumab

Subjects
Ixekizumab, Business, international
Abstract

Contract notice: Delivery of medicinal products with the active substance ixekizumab The subject of the public contract is the provision of continuous supplies of medicinal products with the active substance [...]

Published
2020

27. Delivery Of Medicinal Products With The Active Substance Ixekizumab

Subjects
Ixekizumab, Business, international
Abstract

Tenders are invited for Delivery of medicinal products with the active substance ixekizumab The subject of the public contract is the provision of continuous supplies of medicinal products with the [...]

Published
2020

28. Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis

Subjects
United States. Food and Drug Administration, Ixekizumab, Drug approval, Business, international, Law, Taltz (Medication)
Abstract

Taltz (ixekizumab) is the first humanised interleukin (IL)-17A antagonist therapy approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective inflammation signs. The therapy is [...]

Published
2020

29. EULAR 2020: Lillys TALTZ (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis

Subjects
Ixekizumab, Psoriatic arthritis, Adalimumab, Arthritis, Psoriasis, Diseases, Business, international, Law, Taltz (Medication), Humira (Medication)
Abstract

(GlobeNewswire) - TALTZ (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented virtually today at the European Congress of Rheumatology 2020 [...]

Published
2020

30. Lilly bags expanded EU approval for Taltz

Subjects
Eli Lilly and Co., Back pain -- Care and treatment, Ixekizumab, Pharmaceutical industry, Pain management, Inflammation, Ankylosing spondylitis, Spondylitis, Business, international, Law, Taltz (Medication)
Abstract

The European Medicines Agency has expanded the reach of Lilly's Taltz (ixekizumab) to include the treatment of adults with active ankylosing spondylitis and active non-radiographic axial spondyloarthritis (nr-axSpA). In both [...]

Published
2020

31. EULAR 2020: Lilly's TALTZ(R) (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis

Subjects
Eli Lilly and Co., Ixekizumab, Psoriatic arthritis, Adalimumab, Arthritis, Psoriasis, Diseases, Banking, finance and accounting industries, Business, Taltz (Medication), Humira (Medication)
Abstract

TORONTO, June 05, Jun 05, 2020 (GLOBE NEWSWIRE via COMTEX) -- TALTZ (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented [...]

Published
2020

32. Wound Debridement Products Market Size Analysis, Growth Value, Emerging Trends, Future Insights and Competitive Outlook By 2023

Subjects
Misonix Inc. -- Product introduction -- Market research, Monoclonal antibodies -- Growth, Market research, Scientific equipment industry -- Industry forecasts -- Product introduction -- Market research -- Market size, Ixekizumab, Backup software, Brodalumab, Secukinumab, Ustekinumab, Adalimumab, Industrial research, Company growth, Marketing research, Business, Business, international
Abstract

M2 PRESSWIRE-June 5, 2020-: Wound Debridement Products Market Size Analysis, Growth Value, Emerging Trends, Future Insights and Competitive Outlook By 2023 (C)1994-2020 M2 COMMUNICATIONS RDATE:04062020 Wound Debridement Products Market size [...]

Published
2020

33. EULAR 2020: Lilly's Taltz(r) (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis

Subjects
Eli Lilly and Co., Ixekizumab, Pharmaceutical industry, Psoriatic arthritis, Adalimumab, Arthritis, Psoriasis, General interest, News, opinion and commentary, Taltz (Medication), Humira (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following press release: Taltz(r) (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to [...]

Published
2020

34. FDA APPROVALS ROUNDUP: TAUVID, ORIAHNN, SIRTURO

Subjects
Ipilimumab, Tetracyclines, Atezolizumab, Ixekizumab, Bedaquiline, Florbetaben F18, Ticagrelor, Florbetapir, Ramucirumab, Bevacizumab, Nivolumab, Flutemetamol, Drug approval, Alzheimer's disease, Tomography, Positron emission tomography, Elagolix, Diseases, News, opinion and commentary, Sirturo (Medication)
Abstract

ROCKVILLE, MD -- The following information was released by the Regulatory Affairs Professionals Society: Tauvid nabs approval as first drug to aid imaging of tau pathology FDA has approved Avid [...]

Published
2020

35. Gun violence continues to surge in Chicago

Subjects
Ixekizumab, Gun violence, Murder, News, opinion and commentary, Sports and fitness
Abstract

CHICAGO -- A surge of gun violence over the past two weekends in Chicago is continuing with more than 20 people shot in a 12-hour period. The spate of shootings [...]

Published
2020

36. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*: VOLUNTARY ANNOUNCEMENT- UPDATE ON PROGRESS FOR RECOMBINANT HUMANIZED ANTI-IL-17A MONOCLONAL ANTIBODY INJECTION

Subjects
Secukinumab, Ixekizumab, Monoclonal antibodies, Antibodies, Corporate directors, Clinical trials, General interest, News, opinion and commentary
Abstract

Hong Kong: SHANGHAI JUNSHI BIOSCIENCES CO., LTD. has issued the following announcement: This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (Shang Hai Jun Shi Sheng Wu Yi Yao [...]

Published
2020

37. CHMP BACKS EIGHT NEW MEDICINES, WAITING ON REMDESIVIR APPLICATION

Subjects
Gilead Sciences Inc., Canagliflozin, Apixaban, Vaccines, Ebola virus, Olaparib, Remdesivir, Ixekizumab, Nintedanib, Biological products industry, News, opinion and commentary
Abstract

ROCKVILLE, MD -- The following information was released by the Regulatory Affairs Professionals Society: By Michael Mezher The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) [...]

Published
2020

38. RESEARCHERS SUGGEST INCREASED RISK OF RESPIRATORY-TRACT INFECTIONS IN PEOPLE ON CERTAIN PSORIASIS TREATMENT

Subjects
Interleukins -- Research -- Health aspects, Coronaviruses -- Health aspects -- Research, Monoclonal antibodies -- Research, Disease susceptibility -- Drug therapy -- Research, Medical research -- Health aspects, Psoriasis -- Research -- Drug therapy, Infection -- Drug therapy -- Research, Ixekizumab, Lung diseases, Brodalumab, Secukinumab, Diseases, News, opinion and commentary
Abstract

PHILADELPHIA, PA -- The following information was released by Penn Medicine: Study results suggest further investigation of immunosuppressive qualities of IL-17 inhibitors are needed amidst the coronavirus pandemic May 26, [...]

Published
2020

39. CHMP BACKS EIGHT MEDICINES FOR APPROVAL, RECOMMENDS RANITIDINE SUSPENSION

Subjects
United States. Food and Drug Administration, Sofosbuvir, Cabazitaxel, Ivacaftor, Ixekizumab, Daratumumab, Fingolimod, Asthma, Anidulafungin, Paliperidone, Insulin aspart, Encorafenib, Ranitidine, Respiratory system agents, Drugs, Ravulizumab, Glasdegib, News, opinion and commentary
Abstract

ROCKVILLE, MD -- The following information was released by the Regulatory Affairs Professionals Society: By Michael Mezher At its meeting earlier this week, the European Medicines Agency's (EMA) Committee for [...]

Published
2020

40. Psoriasis Treatment Market Trends: In-Depth Analysis on Market Dynamics, Segmentation & Emerging Growth Factors 2025

Subjects
Tumor necrosis factor -- Forecasts and trends -- Reports, Monoclonal antibodies -- Reports -- Forecasts and trends, Market research -- Reports -- Forecasts and trends, Psoriasis -- Drug therapy, Vitamin D -- Market research, T cells -- Reports -- Forecasts and trends, Etanercept, Infliximab, Nonprescription drugs, Necrosis, Vitamins, Tumors, Topical drugs, Ixekizumab, Brodalumab, Methotrexate, Ustekinumab, Adalimumab, Marketing research, Market trend/market analysis, General interest
Abstract

New Delhi, April 30 -- Psoriasis Treatment Market Research Report: Information by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), InterleU.K.in-Inhibitors (Ustekinumab, SecU.K.inumab, Ixekizumab and Brodalumab), Vitamin D [...]

Published
2020

41. Lilly Gets USFDA Nod For Taltz(Ixekizumab) For Pediatric Patients With Moderate To Severe Plaque Psoriasis

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Child health, Ixekizumab, Psoriasis -- Drug therapy, Pediatrics, Pharmaceutical industry, Drug approval, Childhood, Phototherapy, Youth, Business, international, Law, Taltz (Medication)
Abstract

Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection, 80 mg/mL for the [...]

Published
2020

42. Salimetrics' Growing List of Cytokines Which Can Be Reliably Tested in Saliva Now Includes IL-17A, IL-5, and IL-7 for Fast, Easy Salivary Biomarker Analysis

Subjects
Benralizumab -- Research -- Analysis, Cytokines -- Analysis, B cells -- Analysis, Inflammation -- Research -- Analysis, Monoclonal antibodies -- Research -- Analysis, Tumor necrosis factor, Anti-inflammatory agents, Ixekizumab, Reslizumab, Infection, Secukinumab, Business, general
Abstract

CARLSBAD, Calif. (PRWEB) April 01, 2020 Salimetrics' original panel of cytokines validated in saliva integrated the four popular cytokines IL-1 Beta, IL-6, IL-8, and TNF-Alpha so that researchers could immediately [...]

Published
2020

43. Lilly's Taltz(r) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Child health, Ixekizumab, Psoriasis -- Drug therapy, Pediatrics, Pharmaceutical industry, Drug approval, Childhood, Phototherapy, Youth, General interest, News, opinion and commentary, Taltz (Medication)
Abstract

Dublin: Eli Lilly has issued the following press release: Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License [...]

Published
2020

44. Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Subjects
United States. Food and Drug Administration, Eli Lilly and Co., Child health, Ixekizumab, Psoriasis -- Drug therapy, Pediatrics, Pharmaceutical industry, Drug approval, Childhood, Phototherapy, Youth, Business, international, Law, Taltz (Medication)
Abstract

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection, 80 mg/mL for [...]

Published
2020

45. Health Canada has approved TALTZ(r) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Subjects
Ankylosing spondylitis -- Care and treatment, Ixekizumab, Psoriasis -- Care and treatment, Respiratory system agents, Arthritis, Psoriatic arthritis, Health, Spondylitis, General interest, News, opinion and commentary, Taltz (Medication)
Abstract

CANADA: Eli Lilly Canada has issued the following press release: Eli Lilly Canada announced today that Health Canada approved TALTZ(r) (ixekizumab) on February 4, 2020, for the treatment of adult [...]

Published
2020

46. Health Canada has approved TALTZ (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Subjects
Ankylosing spondylitis -- Care and treatment, Ixekizumab, Psoriasis -- Care and treatment, Respiratory system agents, Arthritis, Psoriatic arthritis, Health, Spondylitis, Business, international, Law, Taltz (Medication)
Abstract

Eli Lilly Canada announced today that Health Canada approved TALTZ (ixekizumab) on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis (AS), which is also known [...]

Published
2020

47. Psoriasis Drugs Market Size Is Projected to Reach USD 13.1 Billion at a CAGR of 7.3% By 2025

Subjects
Nonprescription drugs -- Forecasts and trends, Tumor necrosis factor -- Forecasts and trends, Monoclonal antibodies -- Forecasts and trends, Dermatologic agents -- Forecasts and trends, Psoriasis -- Drug therapy -- Forecasts and trends, Vitamin D -- Forecasts and trends, Etanercept, Infliximab, Drugs and athletes, Necrosis, Vitamins, Tumors, Topical drugs, Interleukins, Ixekizumab, Drugs, Brodalumab, Methotrexate, Secukinumab, Ustekinumab, Adalimumab, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-February 12, 2020-: Psoriasis Drugs Market Size Is Projected to Reach USD 13.1 Billion at a CAGR of 7.3% By 2025 (C)1994-2020 M2 COMMUNICATIONS RDATE:12022020 Psoriasis Drugs Market Analysis [...]

Published
2020

48. Health Canada OK'd Eli Lilly's Taltz for arthritis of the spine

Subjects
Eli Lilly and Co., Ixekizumab, Psoriasis, Pharmaceutical industry, Arthritis, Ankylosing spondylitis, Antiarthritic agents, Psoriatic arthritis, Health, Spondylitis, General interest, News, opinion and commentary, Taltz (Medication)
Abstract

Health Canada has approved Eli Lilly's (NYSE:LLY) Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis, a type of arthritis primarily affecting the spine The IL-17 antagonist was [...]

Published
2020

49. Health Canada has approved TALTZ(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Subjects
Eli Lilly and Co., Ankylosing spondylitis -- Care and treatment, Ixekizumab, Psoriasis -- Care and treatment, Respiratory system agents, Arthritis, Psoriatic arthritis, Spondylitis, Banking, finance and accounting industries, Business, Taltz (Medication)
Abstract

TORONTO, Feb 11, 2020 (GLOBE NEWSWIRE via COMTEX) -- Eli Lilly Canada announced today that Health Canada approved TALTZ (ixekizumab) on February 4, 2020, for the treatment of adult patients [...]

Published
2020

50. Lillys diabetes med Trulicity shrugs off Novo Nordisk challenge

Subjects
Novo Nordisk A/S, Empagliflozin, Secukinumab, Type 2 diabetes, Ixekizumab, Dapagliflozin, Erenumab, Pharmaceutical industry, Dulaglutide, Insulin glargine, Semaglutide, Baricitinib, Pricing, Galcanezumab, Business, international, Law, Ozempic (Medication), Trulicity (Medication)
Abstract

Eli Lillys crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results